The safety of fetoscopy: (II). Effect on maternal plasma levels of 13,14-dihydro-15-oxo-prostaglandin F2 alpha.
The concentration of 13,14-dihydro-15-oxo-prostaglandin F2 alpha (PGFM) was measured by radioimmunoassay in peripheral plasma in 62 pregnant women undergoing diagnostic fetoscopy. The mean concentration of PGFM before fetoscopy was 410.1 +/- 115.8 pmol/l (mean +/- S.D.) and the corresponding values at 10 and 20 min following the procedure were 440.9 +/- 125.6 and 394.4 +/- 103.3 pmol/l respectively; these differences were not statistically significant. Neither was there a significant change in the pre-fetoscopy concentration of PGFM in relation to gestational age between the 14th and 23rd week of pregnancy.
D000022:Abortion, Spontaneous / Q000097:blood*; D015237:Dinoprost / Q000031:analogs & derivatives*; D005260:Female; D005332:Fetoscopy / Q000009:adverse effects*; D006207:Half-Life; D006801:Humans; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000009:adverse effects*; D011460:Prostaglandins F / Q000097:blood*; D012306:Risk
D011460:Prostaglandins F; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D015237:Dinoprost